11
Oct
2018
The MIT Biotech Group Alumni: Where Are They Now?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
19
Jun
2018
So You Want To Get Into Biotech…Part 2: Banana Peel? What Banana Peel?
Although learning more about the many ways in which one can get an interview and first job in biotech and pharma helps, that’s not where it ends. Everyone I know in biopharma has stories of dealing with co-workers who just didn’t get what the industry is about, in the interview or during those pivotal first years. This despite a system...Read More
Share:
18
Jun
2018
So You Want To Get Into Biotech…Part 1: Many Stories, Many Paths
When I’m contacted by young scientists finishing up their postdocs or PhDs, far and away the questions I hear most are about the biotech and pharma industries. How do scientists break in, exactly? There’s a lot of interest out there—not simply as an alternative to academia but as a primary goal for bright people wanting to make a tangible difference...Read More
Share:
6
Jun
2018
From Hoop Dreams to the Biopharma Big Time: Rob Perez on The Long Run
Today’s guest on the show is Rob Perez. He grew up in a lower-middle class household in Los Angeles. Had some hoop dreams that never quite materialized. No big deal. Perez found he had a knack for sales, and paid his way through college by working at fitness centers. Chance brought him into the pharmaceutical sales business. He liked meeting...Read More
Share:
28
Mar
2018
Teaching and Mentoring the Next Generation: Vicki Sato on The Long Run Podcast
Today’s guest on The Long Run podcast is Vicki Sato. She’s one of the biotech industry’s pioneers. Sato started out as a classic academic scientist on the Harvard faculty. Beginning in the mid-1980s, and for about 20 years, the next phase of her career was as an executive at Biogen and Vertex Pharmaceuticals. Her fingerprints are all over a number...Read More
Share:
18
Sep
2017
After the Boom: How’s It Going for Big Pharma Vets At Startups?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
17
Aug
2017
We Can Follow Through On Our Own After Charlottesville
[Editor’s Note: Steve Graham of Fenwick & West is one of biotech’s leading corporate attorneys. His book, “Invisible Ink: Navigating racism in corporate America” was published in April.] I spent my first few years of elementary school in segregated schools. Beaches were segregated. The drinking fountains and restrooms were labeled. At movie theatres, colored people were directed to the balcony. At...Read More
Share:
31
Jul
2017
Whither Experts? A Review of The Death of Expertise and Some Thoughts for Biopharma
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
24
Jul
2017
How Agios, Neurocrine Are Striving to Go Commercial, and Hold Onto Their Souls
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
26
Jun
2017
Watershed Moments: When Celgene and Bristol-Myers Squibb Became Deal Winners
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
1
Jun
2017
Atlas Venture Lures Rising Star Away from Polaris
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
31
May
2017
Parting Thoughts from Genzyme CEO David Meeker
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
25
May
2017
12 VCs Who Matter, But You Never Read About
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
24
Apr
2017
David Baltimore on What it Takes to Create the Future
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
22
Apr
2017
Steve Holtzman on Why Biotech Should Stand Up for Science
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
13
Mar
2017
What We Really Need is International Women’s Artificial Intelligence Day
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
17
Feb
2017
Hiring Women Execs in Biotech, VC Firms Is a Moneyball Play (Part 2)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
16
Feb
2017
The Road Not Traveled: Journey of a PhD into the Biotech Business and Finance Industry
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
10
Feb
2017
Pulse Check on Patient-Centricity: 7 Vital Signs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
3
Feb
2017
Hiring Women Execs in Biotech, VC Firms is a Moneyball Play (Part 1): Getting Better Returns
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share: